ArticleJournal of oncology2022

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects.

Hong-Yuan Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.